# Heidelberg Pharma

Source: https://onco.cc/companies/heidelberg-pharma/  
OnCo record `heidelberg-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Heidelberg Pharma is a German company building antibody-drug conjugates around amanitin, a toxin from the death cap mushroom that kills cells by blocking RNA polymerase II, with its lead candidate HDP-101 in multiple myeloma.

## Summary

Heidelberg Pharma, based in Ladenburg near Heidelberg and listed in Frankfurt, develops antibody-targeted amanitin conjugates (ATACs): the payload amanitin inhibits RNA polymerase II, a mechanism distinct from the microtubule and DNA-damaging payloads of most ADCs and active in slowly dividing cells. Its lead candidate HDP-101 targets BCMA in relapsed multiple myeloma, and the platform is licensed to partners including Takeda. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov, from earlier programmes.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Heidelberg Pharma AG
- Tags: ctgov-sponsor
- HQ: Ladenburg
- Type: biotech
- Website: https://heidelberg-pharma.com

## Sources

- Official website: https://heidelberg-pharma.com
- ClinicalTrials.gov: trials led by Heidelberg Pharma: https://clinicaltrials.gov/search?lead=Heidelberg%20Pharma
- Wikipedia: https://en.wikipedia.org/wiki/Heidelberg_Pharma

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [BCMA](https://onco.cc/targets/bcma/)
- companies: [Takeda](https://onco.cc/companies/takeda/)

---
JSON: https://onco.cc/api/v1/entities/heidelberg-pharma.json